YL201
Solid Tumors (SCLC, NPC)
Phase 3Active
Key Facts
About MediLink Therapeutics
A clinical-stage biotech developing proprietary ADC therapies for solid tumors through its TMALIN® platform and global partnerships.
View full company profileSolid Tumors (SCLC, NPC)
A clinical-stage biotech developing proprietary ADC therapies for solid tumors through its TMALIN® platform and global partnerships.
View full company profile